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Abstract
Background: The Oslo Study of Clonidine in Elderly Patients with Delirium (LUCID) is an RCT investigating the
effect of clonidine in medical patients > 65 years with delirium. To assess the dosage regimen and safety measures
of this study protocol, we measured the plasma concentrations and hemodynamic effects of clonidine in the first
20 patients.
Methods: Patients were randomised to clonidine (n = 10) or placebo (n = 10). The treatment group was given a
loading dose (75μg every 3rd hour up to a maximum of 4 doses) to reach steady state, and further 75μg twice
daily until delirium free for 2 days, discharge or a maximum of 7 days. Blood pressure (BP) and heart rate (HR) were
measured just before every dose. If the systolic BP was < 100 mmHg or HR < 50 beats per minute the next dose
was omitted. Plasma concentrations of clonidine were measured 3 h after each drug intake on day 1, just before
intake (day 2 and at steady state day 4–6) and 3 h after intake at steady state (Cmax). Our estimated pre-specified
plasma concentration target range was 0.3–0.7μg/L.
Results: 3 h after the first dose of 75μg clonidine, plasma concentration levels rose to median 0.35 (range 0.24–0.40)
μg/L. Median trough concentration (C0) at day 2 was 0.70 (0.47–0.96)μg/L. At steady state, median C0 was 0.47
(0.36–0.76)μg/L, rising to Cmax 0.74 (0.56–0.95)μg/L 3 h post dose. A significant haemodynamic change from
baseline was only found at a few time-points during the loading doses within the clonidine group. There was
however extensive individual BP and HR variation in both the clonidine and placebo groups, and when comparing the
change scores (delta values) between the clonidine and the placebo groups, there were no significant differences.
Conclusions: The plasma concentration of clonidine was at the higher end of the estimated therapeutic
range. Hemodynamic changes during clonidine treatment were as expected, with trends towards lower
blood pressure and heart rate in patients treated with clonidine, but with dose adjustments based on SBP
this protocol appears safe.
Trial registration: ClinicalTrials.gov NCT01956604, 09.25.2013. EudraCT Number: 2013–000815-26, 03.18.2013.
Enrolment of first participant: 04.24.2014.
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Background
Despite their dominance in the clinical practice of medi-
cine, older people are poorly represented in drug trials
[1]. There are many potential reasons for this, including
heterogeneity due to variations in biological aging, the
wide range of comorbidities and polypharmacy. For in-
formed decisions to be made in older people, however, it
is important that drug trials overcome these challenges.
Delirium is a disturbance in attention, awareness and
cognition with acute onset resulting from medical ill-
ness, trauma, surgery or drugs. Delirium affects 20% of
hospitalised patients [2] and is associated with poor out-
comes [3]. Drugs are widely used in the treatment of de-
lirium [4, 5], despite the lack of positive evidence of
their effectiveness [6, 7]. The pathogenesis is not well
understood, but one prominent hypothesis is that delir-
ium may in part result from exaggerated and/or pro-
longed stress responses [8].
Dexmedetomidine, a parenterally administered
alpha2-adrenergic receptor agonist which attenuates
sympathetic nervous system activity [9], shows prom-
ise as treatment for delirium in intensive care units
(ICU) [10–16]. A recently published RCT showed that
prophylactic low-dose dexmedetomidine significantly de-
creased occurrence of post-operative delirium [17]. In-
deed, it is now in clinical use in the USA and Europe [18].
However, most patients with delirium are outside of ICUs,
where intravenous use of dexmedetomidine is not feasible.
An alternative agent is orally administered clonidine,
which has very similar pharmacological properties to dex-
medetomidine [19], even though its alpha-2-adrenergic se-
lectivity is lower [20]. Clonidine in delirium is poorly
studied, but a pilot study showed that the use of clo-
nidine infusion during the weaning period after sur-
gery for type-A aortic dissection might reduce the
severity of delirium [21].
The Oslo Study of Clonidine in Elderly Patients with
Delirium (LUCID) is an RCT designed to investigate the
effectiveness of clonidine as a treatment for delirium in
geriatric medical patients [22]. The properties of cloni-
dine make it challenging to anticipate the right dosage
to achieve an appropriate balance between efficacy and
safety in older patients. Most pharmacological studies of
clonidine have been conducted in younger adults [23–
25] or in children [26, 27]. Concentrations of clonidine
known to have clinical effects in adults range from 0.2
to 2.0 μg/L [24, 25, 27]. After oral administration the
maximum plasma concentration (Cmax) occurs after 1–
3 h [23]; higher doses yield proportionately higher con-
centrations [25]. The metabolism of clonidine is hepatic,
mainly through CYP2D6 [28], but varying amounts of
unmetabolised clonidine are excreted by the kidneys.
The reduction in mean arterial pressure (MAP), as well
as the risk of side effects like sedation and dry mouth, is
highest when the plasma concentration of clonidine
peaks (i.e. between 2 and 3 h after administration), even
though only the hemodynamic effects (i.e. blood pres-
sure and heart rate) correlate with the concentration
levels [25].
To the best of our knowledge, there are no studies on
the safety of clonidine and its hemodynamic effects in
geriatric hospitalized patients with delirium. This study
aims to investigate in detail the dosage regimen of cloni-
dine in the LUCID protocol through measuring both
plasma concentrations and hemodynamic effects. We
aimed for the intermediate to low levels, that is, between
0.3 and 0.7 μg/L, because higher plasma concentration
levels may increase the risk of adverse events, including
hypotension, whereas plasma concentration levels lower
than 0.3 μg/L might be insufficient to give a significant
clinical effect.
Methods
LUCID is a randomised, placebo-controlled, double-blind,
parallel group study with 4-month prospective follow-up
[22]. Acutely admitted medical patients > 65 years with
delirium or subsyndromal delirium are eligible for inclu-
sion. The selection criteria are presented in Table 1. In-
cluded patients were randomised to treatment with oral
clonidine or placebo for a maximum of 7 days. The goal is
to include 100 patients and the primary endpoint is the
trajectory of delirium including measurements of atten-
tion, awareness and cognitive function. However, accord-
ing to the pre-specified protocol, pharmacological analysis
of clonidine and safety of the treatment will be
assessed in the first 20 patients, before the final
protocol for dosage regimen and safety assessments in
the final 80 patients are decided. Our pre-specified
target values were plasma-concentrations 0.3–0.7 μg/
L, but a small number of measurements outside this
range would be considered acceptable.
Study medication
Each capsule (CAPSUGEL) contained either 75 μg
Catapresan (clonidine hydrochloride) or 75 μg placebo,
and was produced and labelled by “Kragerø tablettpro-
duksjon A/S”.
Dosage plan and safety
A loading dose (one capsule every 3rd hour up to a
maximum of 4 doses on day 1) was given to achieve
steady state. Further dosage was one capsule twice daily
(8 am and 8 pm) until delirium free for 2 days, discharge
or a maximum of 7 days treatment, whichever came first
(see Table 2). Blood pressure (BP) and heart rate (HR)
was measured just before every dose. The capsule was
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not given if the systolic BP (SBP) was < 100 mmHg
or HR < 50 beats per minute (bpm). Serum creatinine,
blood glucose, ECG, a clinical assessment of hydra-
tion and the Richmond Agitation Sedation Scale [29]
were scheduled for daily assessments for safety rea-
sons. Orthostatic BP tests were planned at day 5, 6 or
7 at 11.00 (approximately 3 h after drug intake), but
occasionally done on day 4 if study drug was planned
halted following protocol. All adverse events were
recorded.
Measurements and procedures
Venous puncture for collection of plasma was scheduled
3 h after each drug intake on day 1, just before drug in-
take (between 8 am and 9 am on day 2 and day 5, 6 or
7) and 3 h after intake (Cmax) at day (4), 5, 6 or 7. Hep-
arin tubes (4 ml) with blood were collected by venous
puncture and centrifuged (2000G) for 10 min and two
aliquots of at least 250 μl were stored in polypropylene
tubes at − 80 °C pending analyses. Clonidine in plasma
was determined by the method of Muller et al. [30] with
modifications as described by Sulheim et al. [31]. The
Data Monitoring Committee (represented by Leiv Otto
Watne) was un-blinded to the randomisation, and iden-
tified the samples from the 10 patients that had received
clonidine for plasma analyses.
Statistical methods
Statistical analyses were performed in SPSS Statistics
version 21 (IBM, Armonk NY) and Prism v7 (Graph Pad
Software Inc., La Jolla, CA, USA).
Due to non-normally distributed data, non-parametric
tests were used to compare continuous variables be-
tween the groups (Mann-Whitney tests) and to compare
paired samples (Wilcoxon signed rank tests). To com-
pare change from baseline to given time points between
the groups, delta values were calculated and compared
with Mann-Whitney U tests. A p-value of < 0.05 was
considered statistically significant.
Results
Between April 2014 and February 2017, of 407 inpatients
considered to probably have delirium, 20 patients ful-
filled the selection criteria and were included in LUCID
and randomised to either clonidine (n = 10) or placebo
(n = 10). Median age was 86 years (range 66–95), and 13
(65%) were women. Polypharmacy and use of other anti-
hypertensive drugs were common (see Table 3), but
none of the patients were using any known strong
CYP2D6 inhibitors (i.e. fluoxetine/paroxetine [32], bu-
propion [33], quinidine [34], cinacalcet [35] or ritonavir
[36]). See Table 3 for baseline characteristics.
Table 1 Eligibility criteria
Inclusion criteria
• Patient > 65 years old admitted to an acute medical ward
• Delirium or subsyndromal delirium within the last 48 h
• Signed informed consent from patient or relatives including advance
consent for on-going treatment and follow up
Exclusion criteria
• Symptomatic bradycardia, bradycardia due to sick sinus syndrome,
second- or third- degree AV-block (if not treated with pacemaker) or
any other reason causing HRa < 50 bpmb at time of inclusion
• Symptomatic hypotension or orthostatic hypotension, or a systolic
BPc < 120 at the time of inclusion
• Ischemic stroke within the last 3 months or critical peripheral
ischemia
• Acute coronary syndrome, unstable or severe coronary heart disease
(symptoms at minimal physical activity; NYHAd 3 and 4) and
moderate to severe heart failure (NYHA 3 and 4). (Acute coronary
syndrome is defined according to international guidelines)
• A diagnosis of polyneuropathy, phaeochromocytoma or renal
insufficiency (estimated GFRe< 30 ml/min according to the MDRDf
formula)
• Body weight < 45 kg
• Considered as moribund on admission
• Unable to take oral medications
• Current use of tricyclic antidepressants, monoamine reuptake
inhibitors or cyclosporine
• Previously included in this study
• Adverse reactions to clonidine or excipients (lactose, saccharose)
• Not speaking or reading Norwegian
• Any other condition as evaluated by the treating physician
• Admitted to the intensive care unit
aHR = heart rate
bbpm = beats per minute
cBP = blood pressure
dNYHA = New York Heart Association Functional Classification
eGFR = glomerular filtration rate
fMDRD =Modification of Diet in Renal Disease formula for estimated GFR
Table 2 Dosage plan for clonidine
Time Safety Dosage
Day 1 Loading
doses
Systolic BPa must be > 120 mmHg at inclusion (i.e. before the first loading dose). For any
of the subsequent loading doses: If systolic BP is < 100 mmHg, HRb < 50 beats/min, or if
RASSc is − 3 or less no more study medication will be given until the planned
maintenance dose the next morning. If RASS is − 2, the treating physician has to assess if
study medication will be given or not
75 μg every 3rd hour until maximum
4 doses, (e.g.: at 2, 5, 8 and 11 pm)
Day 2–7
Maintenance doses
If systolic BP is < 100 mmHg, HR < 50 beats/min, or if RASS is − 3 or less just before a
planned dose, no study medication will be given until the next planned dose 12 h later.
If RASS is − 2, the treating physician has to assess if study medication will be given or not
75 μg BIDd, at 8–9 am and 8–9 pm
aBP = blood pressure
bHR = heart rate
cRASS = Richmond Agitation Sedation Scale
dBID = bis in die (i.e. twice a day)
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Plasma concentrations
The plasma concentrations in relation to time of drug
administration are shown in Table 4. Three hours after
the first dose of 75 μg clonidine, plasma concentration
rose to median 0.35 μg/L (range 0.24–0.46). Median
trough concentration before drug administration at day
2 was 0.70 (0.47–0.96) μg/L. After 4–6 days of clonidine
treatment, median trough concentration (C0) was 0.47
(0.36–0.76) μg/L, rising to a level of 0.74 (0.56–0.95) μg/
L (Cmax) 3 h after administration of the regular dose of
75 μg clonidine.
Hemodynamic changes during treatment
Hemodynamic variables before and during clonidine
treatment are presented in Table 5 and Fig. 1a and b for
the clonidine and placebo groups, respectively. There
was extensive individual BP variation in both treatment
groups. The change in SBP from baseline to day 2 (delta
values) was median − 16 (range − 61–40) in the
clonidine group and median 7 (range − 40–47) in the
placebo groups, but this difference was not statisti-
cally significant (median difference 21 mmHg (95%CI
-12–44), p = 0.17).
Time points with a significant change from baseline
were only found during the loading dosage regimen at
day 1 within the clonidine group. A reduction in SBP
from median 141 (range 124–190) mmHg at baseline to
135 (81–170) mmHg at day 2 in the intervention group
was also noted, while no reduction was observed in the
placebo group (Table 5). No adverse events were re-
ported related to changes in BP and HR.
A test for orthostatic hypotension was performed in
11/20 patients. In the clonidine group, 1 of 6 patients
had a fall in SBP > 20 mmHg, versus 1 of 5 patients in
the placebo group. During the whole treatment period, a
SBP < 100 mmHg was measured 3 times in the clonidine
group (after the 4th loading dose and in the morning
day 2 in patient no. 10, and in the morning day 2 in pa-
tient no. 5). SBP was also measured < 100 mmHg once
Table 3 Baseline characteristics of study participants, n = 20
Variable Clonidine, n = 10 Placebo, n = 10
Age, years, median (range) 85 (73–94) 88 (66–95)
Female, n/N (%) 6/10 (60) 7/10 (70)
Body mass index, kg/m2, median (range) 23 (19–29) 24 (17–28)
Creatinine at baseline, median (range) 78 (34–128) 88 (32–140)
Number of patients using other antihypertensive drugsa, n/N (%) 8/10 (80) 7/10 (70)
aAntihypertensive drugs used in the clonidine group (patients using the drug, n); metoprolol (5), furosemide (2), nifedipine (2), amlodipine (1), atenolol (1), bisoprolol (1),
candesartan/hydrochlorthiazide (1), nitroglycerin (1) and tamsulosin (1)
Table 4 Clonidine concentrations (μg/L) measured at day 1, day 2 and at steady state
Patient Day 1 Day 2 Steady state Day 4,5 or 6 a
Dose 1 Cmax Dose 2 Cmax Dose 3 Cmax Dose 4 Cmax C0 C0 Cmax
1 0.32 0.74 0.76 0.65 0.76 0.95
2 0.24 0.43 0.67 b b
3 c 0.63 0.56
4 0.34 0.59 0.74 0.91 0.71 0.36
5 0.39 0.77 0.61
6 0.27 0.41 c 0.47 0.41
7 0.46 0.45 0.63 0.74 0.47 0.71
8 0.71 c 0.69 0.92
9 0.40 0.41 0.52 0.82 0.67 b
10 0.35 0.85 1.00 0.96 0.77
Median, μg/L 0.35 0.52 0.74 0.91 0.70 0.47 0.74
Range, μg/L 0.24–0.46 0.41–0.85 0.52–1.00 0.47–0.96 0.36–0.76 0.56–0.95
Missing, n 2 2 5 9 0 5 4
All samples were taken 3 h after administration of clonidine, except for C0 at day 2 and at steady state, taken just before administration of clonidine
aThe samples at steady state were taken at day 4 (patients 5 and 10), day 5 (patients 3, 8 and 9), and day 6 (patients 1, 4, 6 and 7)
bThe treatment was halted early (according to the protocol) and complete steady state measurements were not available
c4th dose not given (according to the protocol as patients were asleep)
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in the placebo group. One patient (patient no. 10, morn-
ing day 2) had one measurement of HR 49, all other HR
measurements were > 50 at all times and no patients had
any relevant ECG changes.
Patient no. 10 had a large drop in SBP from base-
line to day 2 (from 142 to 81 mmHg). This patient
also had the highest plasma concentration level after
the third loading dose (1.0 μg/L), and before the drug
administration on day 2 (0.96 μg/L), but kidney func-
tion and body mass index were within the normal
range. However, as per the protocol, the patient did
not receive the next dose, and the SBP and HR was
within the accepted range during the rest of the treat-
ment (4 days). Considering all 10 intervention pa-
tients, there was no correlation between the clonidine
concentrations and the level of drop of SBP from
baseline to the morning at day 2 (Pearson coefficient
0.271, p = 0.448 (Fig. 2)).
Fig. 1 Panel a shows hemodynamic variables in the clonidine group and Panel b shows variables in the placebo group. Time points: First digit= day
number, second digit = measurement at that day. At day two 2–1 is before morning dose and 2–2 is before evening dose. For panel b, time point 1–
5 is not included in the figure as there were only measurements available from one patient. Median (range) values are displayed. DBP= Diastolic Blood
Pressure SBP= Systolic Blood Pressure HR= Heart rate
Fig. 2 Scatterplot of clonidine concentrations and drop in SBP from
baseline to day 2. There was no significant correlation between the
clonidine concentrations and the level of drop of SBP from baseline
to the morning at day 2. Pearson coefficient 0.271, p = 0.448
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Other adverse events
On the 5th day of treatment one patient in the clonidine
group developed hypertensive pulmonary oedema (SBP
238 mmHg). According to the study protocol the study
drug was halted. The Principal Investigator chose to
report this to The Norwegian Medicines Agency as a
Serious Unexpected Serious Adverse Reaction as causal-
ity may have been possible, although considering the
known pharmacological effects of clonidine, hyperten-
sion caused by the treatment would not be expected.
The patient died 2 weeks later and a follow up report
was filed. In the placebo group two patients died during
the hospital stay or shortly after discharge.
Regarding minor adverse events, two patients in both
the clonidine and the placebo group reported dry
mouth. One patient in the clonidine group experienced
a fall during the treatment, but it was not considered
related to hypotension and there was no orthostatic
hypotension measured in this patient. There were no
significant alterations in blood-glucose or significant
episodes of sedation (RASS -3 or less) in either treat-
ment group.
Missing samples
27 of 70 (39%) scheduled blood samples were missing.
For the planned sample after loading dose 4, 9 of 10
samples were missing (including 3 cases in which the pa-
tients never received the 4th dose). The other reasons
for missing samples were: not all patients were willing to
give repeated blood samples; some patients had veins
that were difficult to puncture, making repeated punc-
tures too uncomfortable; if the patients were asleep at
midnight, we did not wake them up because it could
worsen the delirium. Additionally, one patient (patient
no. 2) was treated only for 3 days and gave no sample in
steady state. No blood samples were lost after collection.
Of the 7 patients that received the 4th loading dose of
clonidine, a control BP 3 h after this last dose was miss-
ing in 2 patients as they were asleep and waking them
up might worsen the delirium.
Discussion
The main findings of this study is that the dosage regi-
men described in the LUCID protocol, with a loading
dose of 75 μg clonidine every 3rd hour up to a max-
imum of 4 doses on day 1 and further 75 μg twice daily,
is generally adequate for target concentration of 0.3–0.7
μg/L. However, as the trough concentrations on day 2
were slightly high, a loading dose seems unnecessary
and we propose that a revised dosage regimen of 75 μg
twice daily from day 1 is both adequate and easier to ad-
minister. There was a trend that clonidine had an effect
on BP and HR also in these geriatric medical patients,
and these effects might relate to concentration levels.
Our safety protocol with measurements of BP and HR
before administering clonidine to this patient group thus
proved both necessary and adequate.
The step-wise regimen with repeated doses of 75 μg
every 3rd hour, up to a maximum of 300 μg the first
day, was effective and resulted in plasma concentration
levels at the higher end of the expected therapeutic
range. We aimed for plasma concentration levels be-
tween 0.3 and 0.7 μg/L, and calculated theoretically that
Cmax at day one should be lower than 1.2 μg/L [22]. No
measurements showed higher values than 1.0 μg/L, but
many samples are missing after the last dose at day 1,
and so we cannot rule out that some patients had con-
centrations above 1.2 μg/L. Also, the trough concentra-
tion at day 2 was at the higher end of our pre-specified
target concentration, and would rise further after the
next dose (even though this was not measured in this
study). The three patients that only received 3 loading
doses had among the lower values at day 2 as expected.
A few patients had some measurements higher than 0.7
μg/L, and no patients had lower levels than 0.3 μg/L on
day 2. Based on our findings of some concentration
levels higher than expected and trough concentrations
in the higher end at day 2, we suggest a loading dose is
unnecessary and a dosage regimen of 75 μg twice daily
from day 1 is both adequate and easier to administer.
Examining the response from the very first dose of 75
μg clonidine, the median plasma concentration level
(0.35 μg/L) was already within our pre-specified ex-
pected range. This finding is in line with previously pub-
lished studies of plasma concentrations of clonidine in
younger adults [23] where it was shown that a single
dose of 75 μg clonidine gave concentration max of 0.285
(+/− 0.001) ng/ml. That study seemingly had a lower
inter-patient variability than we found, possibly due to a
healthier, younger population. We chose a single
time-point for Cmax concentration measures (3 h post
dose). As the time (Tmax) from intake to Cmax varies
inter-individually, our variability might simply be a re-
flection of this. Several repeated samples (e.g. from
in-dwelling cannulas) could have given more accurate
measures of Tmax and thus Cmax for every patient. How-
ever, in our population of frail, elderly patients even
more blood samples, or the use of in-dwelling cannulas,
would raise both practical and ethical issues. Also, we
assume that by collecting samples at a time correspond-
ing with a late Tmax (i.e. 3 h) we will still be relatively
close to Cmax even in patients who may have a shorter
Tmax, given the relatively long half-life of clonidine (be-
tween 5 to 25.5 h).
The clonidine concentration levels measured at steady
state (day 4–6) were also within the target range. After
the initial loading doses, clonidine 75 μg twice daily was
sufficient to reach trough concentrations (C0) at median
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0.47 μg/L, rising to a median level of 0.74 μg/L (Cmax)
after intake of another 75 μg clonidine. These results are
also in line with previous studies. In a study of adoles-
cents with chronic fatigue syndrome, a dosage of 50 μg
twice per day for 14 days resulted in median C0 at 0.21
μg/L, rising to median 0.41 μg/L (Cmax) 2 h after admin-
istration of one regular dose of 50 μg [26]. In subjects
receiving oral clonidine 100 μg twice per day for 6 weeks,
plasma concentration ranged between 0.4 and 0.7 μg/L
(2 h after intake of 100 μg) [25]. Another study found
that a single dose of 75 μg gave a Cmax of 0.66 μg/L after
achieving steady state with two 75 μg doses [37].
Clonidine has well known antihypertensive effects and
it also lowers the heart rate [37]. The maximum
hypotensive effect and degree of bradycardia are related
to dose and peak plasma concentrations [23]. Therefore,
the hemodynamic changes with a trend of lower BP and
HR during clonidine treatment were as expected as we
reached the assumed therapeutic concentrations. The
changes in BP and HR in patients treated with clonidine
were not significantly larger than in the placebo group.
Wide 95% confidence intervals indicate that this is likely
due to the low number of participants as the trend was
clearly present in the clonidine group and not in the pla-
cebo group. Our main goal was, however, not to formally
establish differences in BP between the clonidine and
the placebo group. In order to ensure sufficient statis-
tical power for this comparison, a much larger study
would have been necessary. It has previously been
shown that there is a correlation between plasma con-
centration levels and drop in SBP [25]. In this group as a
whole we could not statistically confirm this, but again
this might be due to the small sample size.
Also, a great variability in blood pressure and heart
rate values would be expected in a geriatric hospital
population due to the natural course of the illnesses and
other treatment received. Notably, even if the median
blood pressure and heart rate values were lower in the
patients that received clonidine, the values were not
below that what would be generally considered safe and
adverse symptoms were not reported related to changes
in BP and HR. So, even if the plasma concentration
levels of clonidine occasionally were higher than 0.7 μg/
L, this dosage regimen did not have any hemodynamic
effects considered unsafe.
Large variability in the half-life of clonidine has previ-
ously been reported, and for elderly patients who tend to
have an increase in volume of distribution of lipid sol-
uble drugs [38] (like clonidine) such an increase of
half-life would be expected to be more frequent.
Half-life was however not estimated in this study. Effects
of polypharmacy and interactions related to metabol-
izing enzymes are another source of variability and
heterogeneity. To avoid known interactions, a few
drugs were listed as exclusion criteria and to our
knowledge; none of the medications used in our pa-
tients are strong CYP2D6 inhibitors. However, several
other antihypertensive medications were in use affect-
ing the BP variation. Also, in this elderly population a
varying degree of reduction of renal and hepatic
clearance must be expected. Dose adjustments based
on renal function is recommended, and thus an eligi-
bility criterion of eGFR > 30 was chosen as it was not
feasible to include individual dose adjustments in our
protocol. For hepatic function, the manufacturer sug-
gests no dose adjustments. Accordingly, no dose ad-
justments or safety measures of liver function were
included.
Patient no. 10 illustrates the difficulties in predict-
ing individual effects on BP. The patient had a large
reduction in SBP during the first day of treatment,
but both the kidney function and the body mass
index were within the normal range, and the patient
did not otherwise differ from the other patients re-
ceiving clonidine. Many of these issues are not unique
to clonidine, but illustrate some of the challenges in
administering drugs in the geriatric population. This
emphasizes the importance of clinical efficacy mea-
surements for safety assessments.
The reasons for missing samples illustrate some of the
feasibility issues with intensive follow-up studies in this
population. Despite signalising a positive attitude at in-
clusion, not all patients were willing to give repeated
blood samples. In other cases, we had to consider what
was best for the patients (i.e. veins that were difficult to
puncture, making repeated punctures too uncomfort-
able; and the risk of worsening delirium if the patient
was asleep). Pharmacological studies are rarely per-
formed in elderly patients, and in future studies these
challenges must be taken into account in the study de-
sign both regarding sample schedules (e.g. timing of
samples; which are the most crucial and which can be
‘optional’) and sample size (anticipating the proportion
of samples likely to be missed).
This study is part of a well-designed RCT with a
pre-published protocol. The study included a real-life,
placebo-treated control group in the assessment of
hemodynamic changes. There was a clear pre-defined
prediction of plasma concentration levels, based on
theoretical calculations. The patients were monitored
very closely; safety and optimal clinical care of the
patients was the priority. Some limitations of the
study need to be acknowledged. Some planned plasma
concentration samples are missing. The sample size
was small. Additionally, because of the strict exclu-
sion criteria, the external validity of our findings
might be limited, at least regarding the pharmacody-
namic effects of clonidine.
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Conclusion
The main finding of this study is that a dosage regimen,
as described in the LUCID protocol, with a loading dose
of 75 μg every 3rd hour up to a maximum of 4 doses on
day 1 and further 75 μg twice daily, seems safe, with the
limitation that this is based on a small sample size. For a
target concentration of 0.3–0.7 μg/L, a loading dose is
unnecessary and we propose that a dosage regimen of
75 μg twice daily from day 1 is both adequate and easier
to administer. There was a clear trend that clonidine has
an effect on BP and HR, which might relate to concen-
tration levels, and we believe a safety protocol with mea-
surements of BP and HR before administering clonidine
to this patient group is both a necessary and a sufficient
precaution. We also found that this geriatric population
does have a higher inter-patient variability of plasma
concentration levels compared to previous studies done
in healthier, younger populations, which illustrates the
difficulties of geriatric pharmacological treatment and
supports the need for clinical efficacy measurements for
these patients.
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